ERBB2 and breast carcinoma: On the other hand, it has recently been shown that HER2+breast cancer is resistant to targeted therapy when ERK1/2 kinase activity islow, and that high kinase activity is a prognostic biomarker of tumorsensitivity to therapy [50].